Women’s Insight Lounge

CD47 targeting therapeutics represent a promising frontier in modern cancer treatment, focusing on enhancing the body’s natural immune response against tumor cells. CD47 is a protein often overexpressed on cancer cells, acting as a “don’t eat me” signal that helps them evade destruction by immune cells such as macrophages.

By blocking this signal, CD47-targeted therapies enable the immune system to eliminate malignant cells more effectively. This innovative approach is gaining attention for its potential to treat a wide range of cancers, including leukemia, lymphoma, and solid tumors, offering new hope for patients who may not respond to conventional treatments.